MedTrace Logo

LeucoPatch in Malleoli Ulcer Study

NCT02958072 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-11-21

No results posted yet for this study

Summary

An International Multicenter study evaluation, off the effect of the fully autologous growth factor-containing patch LeucoPatch, on healing of recalcitrant malleoli ulcers.

To compare the impact of LeucoPatch as part of usual care in multidisciplinary Foot clinic settings, versus usual care in the same clinics on malleoli ulcers healing.

Conditions

  • Diabetic Malleoli Ulcers
  • Malleoli Ulcers

Interventions

OTHER

LeucoPatch

LeucoPatch is an fully autologous growth factor-containing dressing

Sponsors & Collaborators

  • Reapplix

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • Nordsjaellands Hospital

    lead OTHER

Principal Investigators

  • Lise Tarnow, Professsor · Nordsjaellands Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2023-03-31
Completion
2023-11-30

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958072 on ClinicalTrials.gov